165 related articles for article (PubMed ID: 32421986)
1. CRISPR-CAS Replacing Antiviral Drugs against HIV: An Update.
Hashmat R; Yousaf MZ; Rahman Z; Anjum KM; Yaqoob A; Imran M
Crit Rev Eukaryot Gene Expr; 2020; 30(1):77-83. PubMed ID: 32421986
[TBL] [Abstract][Full Text] [Related]
2. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
3. In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models.
Yin C; Zhang T; Qu X; Zhang Y; Putatunda R; Xiao X; Li F; Xiao W; Zhao H; Dai S; Qin X; Mo X; Young WB; Khalili K; Hu W
Mol Ther; 2017 May; 25(5):1168-1186. PubMed ID: 28366764
[TBL] [Abstract][Full Text] [Related]
4. A Combinatorial CRISPR-Cas9 Attack on HIV-1 DNA Extinguishes All Infectious Provirus in Infected T Cell Cultures.
Wang G; Zhao N; Berkhout B; Das AT
Cell Rep; 2016 Dec; 17(11):2819-2826. PubMed ID: 27974196
[TBL] [Abstract][Full Text] [Related]
5. Genome scale screening identification of SaCas9/gRNAs for targeting HIV-1 provirus and suppression of HIV-1 infection.
Wang Q; Liu S; Liu Z; Ke Z; Li C; Yu X; Chen S; Guo D
Virus Res; 2018 May; 250():21-30. PubMed ID: 29625148
[TBL] [Abstract][Full Text] [Related]
6. Elimination of infectious HIV DNA by CRISPR-Cas9.
Das AT; Binda CS; Berkhout B
Curr Opin Virol; 2019 Oct; 38():81-88. PubMed ID: 31450074
[TBL] [Abstract][Full Text] [Related]
7. CRISPR-Cas9 Mediated Exonic Disruption for HIV-1 Elimination.
Herskovitz J; Hasan M; Patel M; Blomberg WR; Cohen JD; Machhi J; Shahjin F; Mosley RL; McMillan J; Kevadiya BD; Gendelman HE
EBioMedicine; 2021 Nov; 73():103678. PubMed ID: 34774454
[TBL] [Abstract][Full Text] [Related]
8. Broad-Spectrum and Personalized Guide RNAs for CRISPR/Cas9 HIV-1 Therapeutics.
Dampier W; Sullivan NT; Mell JC; Pirrone V; Ehrlich GD; Chung CH; Allen AG; DeSimone M; Zhong W; Kercher K; Passic S; Williams JW; Szep Z; Khalili K; Jacobson JM; Nonnemacher MR; Wigdahl B
AIDS Res Hum Retroviruses; 2018 Nov; 34(11):950-960. PubMed ID: 29968495
[TBL] [Abstract][Full Text] [Related]
9. A combinational CRISPR/Cas9 gene-editing approach can halt HIV replication and prevent viral escape.
Lebbink RJ; de Jong DC; Wolters F; Kruse EM; van Ham PM; Wiertz EJ; Nijhuis M
Sci Rep; 2017 Feb; 7():41968. PubMed ID: 28176813
[TBL] [Abstract][Full Text] [Related]
10. Viral diversity is an obligate consideration in CRISPR/Cas9 designs for targeting the HIV reservoir.
Roychoudhury P; De Silva Feelixge H; Reeves D; Mayer BT; Stone D; Schiffer JT; Jerome KR
BMC Biol; 2018 Jul; 16(1):75. PubMed ID: 29996827
[TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas9 Ablation of Integrated HIV-1 Accumulates Proviral DNA Circles with Reformed Long Terminal Repeats.
Lai M; Maori E; Quaranta P; Matteoli G; Maggi F; Sgarbanti M; Crucitta S; Pacini S; Turriziani O; Antonelli G; Heeney JL; Freer G; Pistello M
J Virol; 2021 Nov; 95(23):e0135821. PubMed ID: 34549986
[TBL] [Abstract][Full Text] [Related]
12. Excision of HIV-1 DNA by gene editing: a proof-of-concept in vivo study.
Kaminski R; Bella R; Yin C; Otte J; Ferrante P; Gendelman HE; Li H; Booze R; Gordon J; Hu W; Khalili K
Gene Ther; 2016 Aug; 23(8-9):690-5. PubMed ID: 27194423
[TBL] [Abstract][Full Text] [Related]
13. The Impact of HIV-1 Genetic Diversity on CRISPR-Cas9 Antiviral Activity and Viral Escape.
Darcis G; Binda CS; Klaver B; Herrera-Carrillo E; Berkhout B; Das AT
Viruses; 2019 Mar; 11(3):. PubMed ID: 30871200
[TBL] [Abstract][Full Text] [Related]
14. A CRISPR/Cas9 guidance RNA screen platform for HIV provirus disruption and HIV/AIDS gene therapy in astrocytes.
Huang Z; Nair M
Sci Rep; 2017 Jul; 7(1):5955. PubMed ID: 28729655
[TBL] [Abstract][Full Text] [Related]
15. Combinatorial CRISPR-Cas9 and RNA Interference Attack on HIV-1 DNA and RNA Can Lead to Cross-Resistance.
Zhao N; Wang G; Das AT; Berkhout B
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28893790
[TBL] [Abstract][Full Text] [Related]
16. CRISPR-Cas attack of HIV-1 proviral DNA can cause unintended deletion of surrounding cellular DNA.
Liu Y; Binda CS; Berkhout B; Das AT
J Virol; 2023 Dec; 97(12):e0133423. PubMed ID: 37982648
[TBL] [Abstract][Full Text] [Related]
17. CRISPR-Cas based antiviral strategies against HIV-1.
Wang G; Zhao N; Berkhout B; Das AT
Virus Res; 2018 Jan; 244():321-332. PubMed ID: 28760348
[TBL] [Abstract][Full Text] [Related]
18. Multiplexed
Ophinni Y; Miki S; Hayashi Y; Kameoka M
Viruses; 2020 Oct; 12(11):. PubMed ID: 33126728
[TBL] [Abstract][Full Text] [Related]
19. Multiplexed Simian Immunodeficiency Virus-Specific Paired RNA-Guided Cas9 Nickases Inactivate Proviral DNA.
Smith LM; Ladner JT; Hodara VL; Parodi LM; Harris RA; Callery JE; Lai Z; Zou Y; Raveedran M; Rogers J; Giavedoni LD
J Virol; 2021 Nov; 95(23):e0088221. PubMed ID: 34549979
[TBL] [Abstract][Full Text] [Related]
20. Synthetic gRNA/Cas9 Ribonucleoprotein Inhibits HIV Reactivation and Replication.
Khanal S; Cao D; Zhang J; Zhang Y; Schank M; Dang X; Nguyen LNT; Wu XY; Jiang Y; Ning S; Zhao J; Wang L; Gazzar ME; Moorman JP; Yao ZQ
Viruses; 2022 Aug; 14(9):. PubMed ID: 36146709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
